The Bipolar Depression market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bipolar Depression pipeline products will significantly revolutionize the Bipolar Depression market dynamics.  

Bipolar Depression Overview

Bipolar disorder (BD) is a mental disorder characterized by mood swings between depression and mania. Based on the characteristic of the episodes, BD is majorly classified into BD-I, BD II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS).

Some of the key facts of the Bipolar Depression Market Report: 

• The Bipolar Depression market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
• In the United States, the total number of diagnosed prevalent cases of Bipolar Depression was 2,401,287 cases in the year 2020 
• In EU5 the total diagnosed prevalent cases of Bipolar Depression were 1,004,168 cases, in the year 2020 
• The National Institute of Mental Health (NIMH), a part NIH, stated that based on diagnostic interview data from National Comorbidity Survey Replication (NCS-R), the 12-Month prevalence of bipolar disorder among United States adults aged 18 or older was found to be 2.8% 
• Key Bipolar Depression Companies: Intra-Cellular Therapies,Otsuka, Lundbeck, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, Celon Pharma, NeuroRx, and others 
• Key Bipolar Depression Therapies: Caplyta (Lumateperone; ITI-007), NRX-100, NRX-101, Rexulti, Rxulti (Brexpiprazole), SEP-4199, COMP 360 (Psilocybin Therapy), Falkieri (Esketamine DPI), and others 

Get a Free sample for the Bipolar Depression Market Report 

Key benefits of the Bipolar Depression Market report:

1. Bipolar Depression market report covers a descriptive overview and comprehensive insight of the Bipolar Depression Epidemiology and Bipolar Depression market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Bipolar Depression market report provides insights on the current and emerging therapies.
3. Bipolar Depression market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Bipolar Depression market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Bipolar Depression market.

Discover more about therapies set to grab major Bipolar Depression market share @ Bipolar Depression market forecast

Bipolar Depression Epidemiology Segmentation:

The Bipolar Depression market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Bipolar Depression
• Prevalent Cases of Bipolar Depression by severity
• Gender-specific Prevalence of Bipolar Depression
• Diagnosed Cases of Episodic and Chronic Bipolar Depression 

Bipolar Depression Market  

The dynamics of the Bipolar Depression market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as SEP-4199, COMP 360, and others during the forecasted period 2019-2032. 

Download the report to understand which factors are driving Bipolar Depression epidemiology trends @ Bipolar Depression Epidemiological Insights 

Bipolar Depression Market Drivers

• Future Directions in Blood Biomarkers
• Advances Toward Precision Medicine for Bipolar Depression
• Increase in Awareness and Technology

Bipolar Depression Therapies and Key Companies

• Caplyta (Lumateperone; ITI-007): Intra-Cellular Therapies
• NRX-100/ NRX-101: NeuroRx
• Rexulti/Rxulti (Brexpiprazole): Otsuka/ Lundbeck
• SEP-4199: Sunovion (Sumitomo Dainippon Pharma)
• COMP 360 (Psilocybin Therapy): COMPASS Pathways
• Falkieri (Esketamine DPI): Celon Pharma

Scope of the Bipolar Depression Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bipolar Depression Companies: Intra-Cellular Therapies,Otsuka, Lundbeck, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, Celon Pharma, NeuroRx, and others
• Key Bipolar Depression Therapies: Caplyta (Lumateperone; ITI-007), NRX-100, NRX-101, Rexulti, Rxulti (Brexpiprazole), SEP-4199, COMP 360 (Psilocybin Therapy), Falkieri (Esketamine DPI), and others
• Bipolar Depression Therapeutic Assessment: Bipolar Depression current marketed and Bipolar Depression emerging therapies
• Bipolar Depression Market Dynamics:  Bipolar Depression market drivers and Bipolar Depression market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Bipolar Depression Market Access and Reimbursement 

Bipolar Depression Market Barriers

• Misdiagnosis of Bipolar Depression
• Unsatisfactory Design of RCTs 
• Limited Understanding of the Disease Mechanism

Table of Contents 

1. Bipolar Depression Market Report Introduction

2. Executive Summary for Bipolar Depression

3. SWOT analysis of Bipolar Depression

4. Bipolar Depression Patient Share (%) Overview at a Glance

5. Bipolar Depression Market Overview at a Glance

6. Bipolar Depression Disease Background and Overview

7. Bipolar Depression Epidemiology and Patient Population

8. Country-Specific Patient Population of Bipolar Depression 

9. Bipolar Depression Current Treatment and Medical Practices

10. Bipolar Depression Unmet Needs

11. Bipolar Depression Emerging Therapies

12. Bipolar Depression Market Outlook

13. Country-Wise Bipolar Depression Market Analysis (2019–2032)

14. Bipolar Depression Market Access and Reimbursement of Therapies

15. Bipolar Depression Market Drivers

16. Bipolar Depression Market Barriers

17.  Bipolar Depression Appendix

18. Bipolar Depression Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Bipolar Depression treatment, visit @ Bipolar Depression Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/